MicroRNA Nanotherapeutics for Lung Targeting. Insights into Pulmonary Hypertension
1
Center for Cooperative Research in Biomaterials (CIC biomaGUNE), Basque Research and Technology Alliance (BRTA), Paseo de Miramón 182, 20014 San Sebastián, Spain
2
CIBER de Enfermedades Respiratorias (CIBERES), 28029 Madrid, Spain
3
Center for Cooperative Research in Bioscience (CIC bioGUNE), Buiding 800, Science and Technology Park of Bizkaia, 48160 Derio, Spain
4
Ikerbasque, Basque Foundation for Science, 48013 Bilbao, Spain
5
Departamento de Química en Ciencias Farmacéuticas, Universidad Complutense de Madrid, 28040 Madrid, Spain
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2020, 21(9), 3253; https://doi.org/10.3390/ijms21093253
Received: 5 April 2020
/
Revised: 26 April 2020
/
Accepted: 30 April 2020
/
Published: 4 May 2020
(This article belongs to the Special Issue Nanomedicine, Nanopharmacy and Nanobiomaterials)
In this review, the potential future role of microRNA-based therapies and their specific application in lung diseases is reported with special attention to pulmonary hypertension. Current limitations of these therapies will be pointed out in order to address the challenges that they need to face to reach clinical applications. In this context, the encapsulation of microRNA-based therapies in nanovectors has shown improvements as compared to chemically modified microRNAs toward enhanced stability, efficacy, reduced side effects, and local administration. All these concepts will contextualize in this review the recent achievements and expectations reported for the treatment of pulmonary hypertension.
View Full-Text
Keywords:
non-coding RNA; microRNA; replacement therapy; antisense-mediated inhibition; mimicRNA; lung targeting; pulmonary disease; pulmonary hypertension; nanoparticle; liposome
▼
Show Figures
Figure 1
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
MDPI and ACS Style
Carregal-Romero, S.; Fadón, L.; Berra, E.; Ruíz-Cabello, J. MicroRNA Nanotherapeutics for Lung Targeting. Insights into Pulmonary Hypertension. Int. J. Mol. Sci. 2020, 21, 3253. https://doi.org/10.3390/ijms21093253
AMA Style
Carregal-Romero S, Fadón L, Berra E, Ruíz-Cabello J. MicroRNA Nanotherapeutics for Lung Targeting. Insights into Pulmonary Hypertension. International Journal of Molecular Sciences. 2020; 21(9):3253. https://doi.org/10.3390/ijms21093253
Chicago/Turabian StyleCarregal-Romero, Susana, Lucía Fadón, Edurne Berra, and Jesús Ruíz-Cabello. 2020. "MicroRNA Nanotherapeutics for Lung Targeting. Insights into Pulmonary Hypertension" International Journal of Molecular Sciences 21, no. 9: 3253. https://doi.org/10.3390/ijms21093253
Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.
